Nordic Nanovector ASA has raised NOK 231 million ($25 million) in a private share placement to support Betalutin, an antibody radionuclide conjugate that is being developed for follicular lymphoma, a type of non-Hodgkin’s lymphoma. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
